Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.

Chen T, Sorna V, Choi S, Call L, Bearss J, Carpenter K, Warner SL, Sharma S, Bearss DJ, Vankayalapati H.

Bioorg Med Chem Lett. 2017 Dec 15;27(24):5473-5480. doi: 10.1016/j.bmcl.2017.10.041. Epub 2017 Oct 28.

PMID:
29150397
2.

Getting political about patient advocacy.

Warner SL.

Nursing. 2017 Nov;47(11):47-49. doi: 10.1097/01.NURSE.0000525989.51732.b6. No abstract available.

PMID:
29069060
3.

The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals.

Richmond JA, Sheppard-Law S, Mason S, Warner SL.

Patient Prefer Adherence. 2016 Dec 13;10:2479-2489. doi: 10.2147/PPA.S117757. eCollection 2016.

4.

Productive errors: Transforming learning experiences in healthcare.

Warner SL.

Nurs Manage. 2016 Sep;47(9):36-9. doi: 10.1097/01.NUMA.0000491127.68354.f7. No abstract available.

PMID:
27570921
5.

Myristoylated p110α Causes Embryonic Death Due to Developmental and Vascular Defects.

Sheen MR, Warner SL, Fields JL, Conejo-Garcia JR, Fiering S.

Open Life Sci. 2015 Oct;10(1):461-478. Epub 2015 Oct 19.

6.

Productive errors Transforming learning experiences in healthcare.

Warner SL.

Nursing. 2016 Apr;46(4):57-9. doi: 10.1097/01.NURSE.0000481423.66738.67. No abstract available.

PMID:
27008055
7.

Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.

Sinha S, Boysen J, Nelson M, Warner SL, Bearss D, Kay NE, Ghosh AK.

Leukemia. 2016 Jun;30(6):1431-6. doi: 10.1038/leu.2015.323. Epub 2015 Nov 24. No abstract available.

8.

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.

Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA.

Leukemia. 2015 Dec;29(12):2382-9. doi: 10.1038/leu.2015.147. Epub 2015 Jun 19.

PMID:
26172401
9.

Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.

Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE, Ghosh AK.

Clin Cancer Res. 2015 May 1;21(9):2115-26. doi: 10.1158/1078-0432.CCR-14-1892. Epub 2015 Feb 11.

10.

Inhibition of Nek2 by small molecules affects proteasome activity.

Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ.

Biomed Res Int. 2014;2014:273180. doi: 10.1155/2014/273180. Epub 2014 Sep 17.

11.

Activators of PKM2 in cancer metabolism.

Warner SL, Carpenter KJ, Bearss DJ.

Future Med Chem. 2014 Jun;6(10):1167-78. doi: 10.4155/fmc.14.70. Review.

PMID:
25078136
12.

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DV, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJ.

Leukemia. 2014 Nov;28(11):2251-4. doi: 10.1038/leu.2014.206. Epub 2014 Jul 3. No abstract available.

13.

A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, Albertson DJ, Call LT, Bearss JJ, Tripp S, Liu T, Stephens BJ, Mollard A, Warner SL, Bearss DJ, Kanner SB.

Neoplasia. 2014 May;16(5):403-12. doi: 10.1016/j.neo.2014.05.004. Epub 2014 Jun 18.

14.

High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.

Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, Sharma S.

J Med Chem. 2013 Dec 12;56(23):9496-508. doi: 10.1021/jm400870h. Epub 2013 Nov 23.

PMID:
24237195
15.

The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D, Shanafelt TD, Kay NE, Ghosh AK.

Leukemia. 2014 Feb;28(2):451-5. doi: 10.1038/leu.2013.298. Epub 2013 Oct 18. No abstract available.

16.

TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.

Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT.

Cancer Res. 2013 Nov 1;73(21):6516-25. doi: 10.1158/0008-5472.CAN-13-0967. Epub 2013 Sep 6.

17.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

18.

Clinical, pathological, and genetic characterization of Listeria monocytogenes causing sepsis and necrotizing typhlocolitis and hepatitis in a foal.

Warner SL, Boggs J, Lee JK, Reddy S, Banes M, Cooley J.

J Vet Diagn Invest. 2012 May;24(3):581-6. doi: 10.1177/1040638711436245.

PMID:
22529130
19.

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ.

ACS Med Chem Lett. 2011 Dec 8;2(12):907-912.

20.

Targeting Axl and Mer kinases in cancer.

Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S.

Mol Cancer Ther. 2011 Oct;10(10):1763-73. doi: 10.1158/1535-7163.MCT-11-0116. Epub 2011 Sep 20. Review.

21.

Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors.

Chung JY, Davis JA, Price BD, Staley DM, Wagner MV, Warner SL, Bearss DJ, Hansen MD.

Exp Cell Res. 2011 Feb 1;317(3):307-18. doi: 10.1016/j.yexcr.2010.11.002. Epub 2010 Nov 11.

PMID:
21075102
22.

In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.

Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ.

Exp Hematol. 2011 Jan;39(1):14-25. doi: 10.1016/j.exphem.2010.09.013. Epub 2010 Oct 8.

PMID:
20934482
23.

S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth.

Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, Qiu X, Yoo CB, Jones PA.

Mol Cancer Ther. 2010 May;9(5):1443-50. doi: 10.1158/1535-7163.MCT-09-1048. Epub 2010 May 4.

24.

Exposure to Cigarette Smoke Disrupts CCL20-Mediated Antimicrobial Activity in Respiratory Epithelial Cells.

Crane-Godreau MA, Maccani MA, Eszterhas SK, Warner SL, Jukosky JA, Fiering S.

Open Immunol J. 2009 Jan 1;2:86-93.

25.

Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.

Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H, Von Hoff DD.

Clin Cancer Res. 2009 Nov 1;15(21):6519-28. doi: 10.1158/1078-0432.CCR-09-0077. Epub 2009 Oct 27.

26.

A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis.

Crane DD, Warner SL, Bosio CM.

J Immunol. 2009 Oct 1;183(7):4593-600. doi: 10.4049/jimmunol.0901655. Epub 2009 Sep 14.

27.

Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Warner SL, Muñoz RM, Bearss DJ, Grippo P, Han H, Von Hoff DD.

Pancreas. 2008 Oct;37(3):e39-44. doi: 10.1097/MPA.0b013e318176b9ae.

28.

Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.

Warner SL, Stephens BJ, Von Hoff DD.

Curr Oncol Rep. 2008 Mar;10(2):122-9. Review.

PMID:
18377825
29.

Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.

Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H.

Mol Cancer Ther. 2006 Oct;5(10):2450-8.

30.

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.

Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH.

Mol Cancer Ther. 2006 Jul;5(7):1764-73. Erratum in: Mol Cancer Ther. 2006 Dec;5(12):3312. Mahadevan, Daruka [added].

31.

Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.

Warner SL, Gray PJ, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):436-48. Review.

PMID:
16890798
32.

Targeting Aurora-2 kinase in cancer.

Warner SL, Bearss DJ, Han H, Von Hoff DD.

Mol Cancer Ther. 2003 Jun;2(6):589-95. Review.

33.

Evaluation of a community breast screening promotion program.

Worden JK, Mickey RM, Vacek PM, Flynn BS, Solomon LJ, Secker-Walker RH, Skelly JM, Danigelis NL, Geller BM, Warner SL, Clark RA, Foster RS, Vezina JL, Hooper G.

Prev Med. 2002 Oct;35(4):349-61.

PMID:
12453712
34.

Breast screening behavior and interactions with health care providers among lower income women.

Mickey RM, Vezina JL, Worden JK, Warner SL.

Med Care. 1997 Dec;35(12):1204-11. No abstract available.

PMID:
9413308
35.

The impending crisis awaiting cardiac transplantation. Modeling a solution based on selection.

Stevenson LW, Warner SL, Steimle AE, Fonarow GC, Hamilton MA, Moriguchi JD, Kobashigawa JA, Tillisch JH, Drinkwater DC, Laks H.

Circulation. 1994 Jan;89(1):450-7.

PMID:
8281680
36.

Freud's analysis of Horace Frink, M.D.: a previously unexplained therapeutic disaster.

Warner SL.

J Am Acad Psychoanal. 1994 Spring;22(1):137-52. No abstract available.

PMID:
8206795
37.

Continuing education in the physician's office: a pilot study for breast exams.

Warner SL, Solomon LJ, Foster RS Jr, Worden JK, Atkins E.

Fam Pract Res J. 1993 Jun;13(2):179-83.

PMID:
8517200
38.

Modeling distribution of donor hearts to maximize early candidate survival.

Stevenson LW, Warner SL, Hamilton MA, Moriguchi JD, Chelimsky-Fallick C, Fonarow GC, Kobashigawa J, Drinkwater DC, Laks H.

Circulation. 1992 Nov;86(5 Suppl):II224-30.

PMID:
1424004
39.

A turnover prevention program for child care workers: a failed effort?

Warner SL, Perkins A, McGrath M, Kucinkas C.

Arch Psychiatr Nurs. 1991 Aug;5(4):244-50.

PMID:
1953050
40.

Humor: a coping response for student nurses.

Warner SL.

Arch Psychiatr Nurs. 1991 Feb;5(1):10-6.

PMID:
2039275
41.

Freud's antipathy to America.

Warner SL.

J Am Acad Psychoanal. 1991 Spring;19(1):141-55.

PMID:
2061135
42.

Freud and the mighty warrior.

Warner SL.

J Am Acad Psychoanal. 1991 Summer;19(2):282-93.

PMID:
1938587
43.

Psychoanalytic understanding and treatment of the very rich.

Warner SL.

J Am Acad Psychoanal. 1991 Winter;19(4):578-94.

PMID:
1797750
44.

Princess Marie Bonaparte, Edgar Allan Poe, and psychobiography.

Warner SL.

J Am Acad Psychoanal. 1991 Fall;19(3):446-61.

PMID:
1744021
45.

Psychological studies of Woodrow Wilson: comparing Freud-Bullitt and other psychobiographies.

Warner SL.

J Am Acad Psychoanal. 1990 Fall;18(3):480-93. No abstract available.

PMID:
2258318
46.

Physician interest in breast cancer screening education. A survey of Vermont family physicians.

Warner SL, Worden JK, Solomon LJ, Wadland WC.

J Fam Pract. 1989 Sep;29(3):281-5.

PMID:
2769193
47.

An investment goal.

Warner SL.

Radiol Technol. 1989 Jul-Aug;60(6):535. No abstract available.

PMID:
2762547
48.

Sigmund Freud and money.

Warner SL.

J Am Acad Psychoanal. 1989 Winter;17(4):609-22.

PMID:
2695505
49.

Fourteen Wilsonian points for Freud and Bullitt.

Warner SL.

J Am Acad Psychoanal. 1988 Oct;16(4):479-89. No abstract available.

PMID:
3058661
50.

Third-party payments for nurses: untangling the web.

Warner SL.

Nurs Health Care. 1988 Apr;9(4):180-4. No abstract available.

PMID:
3357579

Supplemental Content

Loading ...
Support Center